J. The Jewish News of Northern California

Second phase of Gaza ceasefire underway, despite remaining hostage

Middle East envoy Steve Witkoff said the second phase entailed “demilitarization, technocratic governance, and reconstruction ...
Business Wire

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 2 CADENCE study evaluating WINREVAIR™ ...
MedCity News

Despite Phase 3 Failure, Sarepta Still Sees Path for Muscle Disease Drugs to Secure Full FDA Approval

Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...
FierceBiotech

Edesa claims survival data win for phase 3 respiratory failure trial

Edesa Biotech has shared data from its truncated phase 3 respiratory failure trial, linking the anti-TLR4 antibody to improvements in survival and recovery. The trial enrolled about 100 people who ...
Frontiers

Phase field modelling of the hydro-mechanical coupling failure mechanisms of fissured rock masses

1 State Key Laboratory of Water Resource Protection and Utilization in Coal Mining, Beijing, China 2 School of Civil Engineering, Qingdao University of Technology, Qingdao, Shandong, China Exploring ...
Novartis

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids 1,2 Patients treated ...
Novartis

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

East Hanover, August 12, 2025 – Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune ...
Reuters

Vertex's trial failure, scrapped study cloud pain drug push; shares slump

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...